

# Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2018

https://marketpublishers.com/r/D42A370C841EN.html

Date: October 2018

Pages: 29

Price: US\$ 3,500.00 (Single User License)

ID: D42A370C841EN

# **Abstracts**

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2018

# **SUMMARY**

According to the recently published report 'Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2018'; Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Diglyceride acyltransferase 1 (DGAT-1) is an enzyme that catalyzes the formation of triglycerides from diacylglycerol and Acyl-CoA. It plays a role in esterifying exogenous fatty acids to glycerol. It functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders.

The report 'Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2018' outlays comprehensive information on the Diacylglycerol O Acyltransferase 1 (Diglyceride



Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase I and Preclinical stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Metabolic Disorders, Gastrointestinal and Immunology which include indications Acne Vulgaris, Dyslipidemia, Hyperlipidemia, Inflammation, Non-Alcoholic Steatohepatitis (NASH) and Obesity.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

#### SCOPE

The report provides a snapshot of the global therapeutic landscape for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)

The report reviews Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and



collaboration details & other developmental activities

The report reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics and enlists all their major and minor projects

The report assesses Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Diacylglycerol O
Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product
1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC
2.3.1.20) targeted therapeutics

#### **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading



# companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT
Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1
or EC 2.3.1.76 or EC 2.3.1.20) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



# **Contents**

Introduction

Global Markets Direct Report Coverage

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related

Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76

or EC 2.3.1.20) - Overview

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related

Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76

or EC 2.3.1.20) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related

Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76

or EC 2.3.1.20) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related

Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76

or EC 2.3.1.20) - Companies Involved in Therapeutics Development

Boston Pharmaceuticals Inc

Viking Therapeutics Inc

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related

Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76

or EC 2.3.1.20) - Drug Profiles

BOS-356 - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

RVT-503 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Small Molecule to Inhibit DGAT1 for Hyperlipidemia - Drug Profile

**Product Description** 



Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DGAT-1 for Inflammation and Metabolic Disorders - Drug

**Profile** 

**Product Description** 

Mechanism Of Action

R&D Progress

SNP-630 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Dormant Products

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

**Expert Panel Validation** 

Contact Us

Disclaimer



# **List Of Tables**

#### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Boston Pharmaceuticals Inc, H2 2018

Pipeline by Viking Therapeutics Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd.1), H2 2018

Discontinued Products, H2 2018



# **List Of Figures**

#### **LIST OF FIGURES**

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Malagula Types 112 2010

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

## **COMPANIES MENTIONED**

Boston Pharmaceuticals Inc Viking Therapeutics Inc



# I would like to order

Product name: Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene

Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC

2.3.1.20) - Pipeline Review, H2 2018

Product link: https://marketpublishers.com/r/D42A370C841EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/D42A370C841EN.html">https://marketpublishers.com/r/D42A370C841EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970